197 related articles for article (PubMed ID: 31718855)
1. Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review.
Beck A; Retèl VP; Bhairosing PA; van den Brekel M; van Harten WH
Health Policy; 2019 Dec; 123(12):1185-1198. PubMed ID: 31718855
[TBL] [Abstract][Full Text] [Related]
2. Patient access to voice prostheses and heat and moisture exchangers: Factors influencing physician's prescription and reimbursement in eight European countries.
Beck ACC; Retèl VP; van den Brekel MWM; van Harten WH
Oral Oncol; 2019 Apr; 91():56-64. PubMed ID: 30926063
[TBL] [Abstract][Full Text] [Related]
3. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
[TBL] [Abstract][Full Text] [Related]
4. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
Ciani O; Wilcher B; van Giessen A; Taylor RS
Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
[TBL] [Abstract][Full Text] [Related]
5. Which barriers prevent the efficient use of resources in medical device sectors?
Simoens S
Appl Health Econ Health Policy; 2009; 7(4):209-17. PubMed ID: 19905034
[TBL] [Abstract][Full Text] [Related]
6. Diabetes device reimbursement in the EU-5.
Schäfer E; Schnell G; Bobáková T
J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
[TBL] [Abstract][Full Text] [Related]
7. An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations.
Tarricone R; Banks H; Ciani O; Brouwer W; Drummond MF; Leidl R; Martelli N; Sampietro-Colom L; Taylor RS
Expert Rev Med Devices; 2023 Apr; 20(4):259-271. PubMed ID: 36987818
[TBL] [Abstract][Full Text] [Related]
8. Considerations for an institution for evaluation of diabetes technology devices to improve their quality in the European Union.
Heinemann L; Freckmann G; Koschinsky T
J Diabetes Sci Technol; 2013 Mar; 7(2):542-7. PubMed ID: 23567012
[TBL] [Abstract][Full Text] [Related]
9. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
[TBL] [Abstract][Full Text] [Related]
10. Balancing adoption and affordability of medical devices in Europe.
Schreyögg J; Bäumler M; Busse R
Health Policy; 2009 Oct; 92(2-3):218-24. PubMed ID: 19410326
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
12. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
[TBL] [Abstract][Full Text] [Related]
13. A full-fledged overhaul is needed for a risk and value-based regulation of medical devices in Europe.
Campillo-Artero C
Health Policy; 2013 Nov; 113(1-2):38-44. PubMed ID: 23602548
[TBL] [Abstract][Full Text] [Related]
14. Neither protective nor harmonized: the crossborder regulation of medical devices in the EU.
Jarman H; Rozenblum S; Huang TJ
Health Econ Policy Law; 2021 Jan; 16(1):51-63. PubMed ID: 32631465
[TBL] [Abstract][Full Text] [Related]
15. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
16. The Physician Payments Sunshine Act--Two Years of the Open Payments Program.
Agrawal S; Brown D
N Engl J Med; 2016 Mar; 374(10):906-9. PubMed ID: 26962725
[No Abstract] [Full Text] [Related]
17. Obtaining reimbursement in France and Italy for new diabetes products.
Schaefer E; Schnell G; Sonsalla J
J Diabetes Sci Technol; 2015 Jan; 9(1):156-61. PubMed ID: 25550411
[TBL] [Abstract][Full Text] [Related]
18. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
Lee SS; Salole E
Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
[TBL] [Abstract][Full Text] [Related]
19. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
Tarricone R; Torbica A; Ferré F; Drummond M
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):707-18. PubMed ID: 25196848
[TBL] [Abstract][Full Text] [Related]
20. [In search of a travel guide-results from a survey of E‑health startup companies].
Hagen J; Lauer W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):291-297. PubMed ID: 29404630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
